AU2004290950A1 - Inhibitor imaging agents - Google Patents

Inhibitor imaging agents Download PDF

Info

Publication number
AU2004290950A1
AU2004290950A1 AU2004290950A AU2004290950A AU2004290950A1 AU 2004290950 A1 AU2004290950 A1 AU 2004290950A1 AU 2004290950 A AU2004290950 A AU 2004290950A AU 2004290950 A AU2004290950 A AU 2004290950A AU 2004290950 A1 AU2004290950 A1 AU 2004290950A1
Authority
AU
Australia
Prior art keywords
imaging
radioactive
imaging agent
pct
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2004290950A
Other languages
English (en)
Inventor
Emma Bjurgert
Alan Cuthbertson
Magne Solbakken
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GE Healthcare Ltd
Original Assignee
GE Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GE Healthcare Ltd filed Critical GE Healthcare Ltd
Publication of AU2004290950A1 publication Critical patent/AU2004290950A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
AU2004290950A 2003-11-14 2004-11-12 Inhibitor imaging agents Abandoned AU2004290950A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0326546.9A GB0326546D0 (en) 2003-11-14 2003-11-14 Inhibitor imaging agents
GB0326546.9 2003-11-14
PCT/GB2004/004792 WO2005049005A1 (en) 2003-11-14 2004-11-12 Inhibitor imaging agents

Publications (1)

Publication Number Publication Date
AU2004290950A1 true AU2004290950A1 (en) 2005-06-02

Family

ID=29726529

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004290950A Abandoned AU2004290950A1 (en) 2003-11-14 2004-11-12 Inhibitor imaging agents

Country Status (16)

Country Link
US (1) US20070104644A1 (enExample)
EP (1) EP1682113B1 (enExample)
JP (1) JP5043438B2 (enExample)
KR (1) KR20060118479A (enExample)
CN (1) CN1901894A (enExample)
AT (1) ATE384519T1 (enExample)
AU (1) AU2004290950A1 (enExample)
BR (1) BRPI0416528A (enExample)
CA (1) CA2545267A1 (enExample)
DE (1) DE602004011553T2 (enExample)
ES (1) ES2299884T3 (enExample)
GB (1) GB0326546D0 (enExample)
MX (1) MXPA06005355A (enExample)
NO (1) NO20062118L (enExample)
RU (1) RU2006117298A (enExample)
WO (1) WO2005049005A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200630337A (en) * 2004-10-14 2006-09-01 Euro Celtique Sa Piperidinyl compounds and the use thereof
WO2007030012A2 (en) * 2005-09-05 2007-03-15 Stichting Voor De Technische Wetenscahappen Extracellular matrix imaging
FR2891830B1 (fr) 2005-10-07 2011-06-24 Guerbet Sa Composes a chaines aminoalcools courtes et complexes metalliques pour l'imagerie medicale
GB0520527D0 (en) * 2005-10-10 2005-11-16 Ge Healthcare Ltd Automated method
ES2357861T3 (es) 2006-02-15 2011-05-03 Ge Healthcare As Agentes de contraste.
US8247442B2 (en) * 2006-03-29 2012-08-21 Purdue Pharma L.P. Benzenesulfonamide compounds and their use
MX2008012387A (es) * 2006-03-29 2008-10-09 Novartis Ag Inhibidores selectivos de mmp basados en hidroxamato.
US8791264B2 (en) * 2006-04-13 2014-07-29 Purdue Pharma L.P. Benzenesulfonamide compounds and their use as blockers of calcium channels
WO2007118854A1 (en) * 2006-04-13 2007-10-25 Euro-Celtique S.A. Benzenesulfonamide compounds and the use thereof
GB0610395D0 (en) * 2006-05-25 2006-07-05 Ge Healthcare Ltd Novel imaging agents
US8273325B2 (en) * 2006-12-20 2012-09-25 Ge Healthcare As Contrast agents
US8399486B2 (en) * 2007-04-09 2013-03-19 Purdue Pharma L.P. Benzenesulfonyl compounds and the use thereof
WO2009040659A2 (en) * 2007-09-28 2009-04-02 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
EP2119690A1 (en) * 2008-05-14 2009-11-18 Academisch Medisch Centrum bij de Universiteit van Amsterdam Radiolabelled MMP selective compounds
JP5322527B2 (ja) * 2008-07-17 2013-10-23 浜松ホトニクス株式会社 アポトーシスの検出に適した化合物
EP2147684A1 (en) * 2008-07-22 2010-01-27 Bracco Imaging S.p.A Diagnostic Agents Selective Against Metalloproteases
WO2010138720A2 (en) * 2009-05-27 2010-12-02 The Scripps Research Institute Compounds and methods for chelating metals in aqueous solutions
JP5837486B2 (ja) * 2009-07-03 2015-12-24 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル カチオン非依存性マンノース６−リン酸受容体を標的とする化合物
US9023318B2 (en) * 2011-06-08 2015-05-05 Siemens Medical Solutions Usa, Inc. Compounds with matrix-metalloproteinase inhibitory activity and imaging agents thereof
US8871189B2 (en) * 2011-11-30 2014-10-28 Mallinckrodt Llc MMP-targeted therapeutic and/or diagnostic nanocarriers
CN103980277B (zh) * 2014-05-27 2016-06-15 青岛大学 一种叶酸巯基化衍生物的制备方法
GB202012671D0 (en) * 2020-08-13 2020-09-30 Nrf Ithemba Labs Theranostic Compounds

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5714465A (en) * 1989-05-19 1998-02-03 Amgen Inc. Method of inhibiting tumor cell dissemination with a metalloproteinase inhibitor
US5863949A (en) * 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
DK0895988T3 (da) * 1997-08-08 2002-09-09 Pfizer Prod Inc Arylsulfonylaminohydroxamsyrederivater
PL338633A1 (en) * 1997-08-08 2000-11-06 Pfizer Prod Inc Derivatives of aryloxyarylsuphonylamino hydroxamic acid
IL127496A0 (en) * 1997-12-19 1999-10-28 Pfizer Prod Inc The use of MMP inhibitors for the treatment of ocular angiogenesis
ES2220004T3 (es) * 1998-04-10 2004-12-01 Pfizer Products Inc. Derivados del acido ciclobutil-ariloxiarilsulfonilaminohidroxamico.
ATE260251T1 (de) * 1999-08-18 2004-03-15 Warner Lambert Co Hydroxamsäurederivate als matrix- metalloproteinase-inhibitoren
IL138686A0 (en) * 1999-10-01 2001-10-31 Pfizer Prod Inc α- SULFONYLAMINO HYDROXAMIC ACID INHIBITORS OF MATRIX METALLOPROTEINASES FOR THE TREATMENT OF PERIPHERAL OR CENTRAL NERVOUS SYSTEM DISORDERS
US6656448B1 (en) * 2000-02-15 2003-12-02 Bristol-Myers Squibb Pharma Company Matrix metalloproteinase inhibitors
EP1309579B1 (en) * 2000-05-30 2005-10-12 Board Of Governors Of Wayne State University Inhibitors of matrix metalloproteinases
CA2514885A1 (en) * 2003-02-10 2004-08-19 Ge Healthcare Limited Diagnostic imaging agents with mmp inhibitory activity

Also Published As

Publication number Publication date
KR20060118479A (ko) 2006-11-23
BRPI0416528A (pt) 2007-01-09
US20070104644A1 (en) 2007-05-10
CN1901894A (zh) 2007-01-24
JP5043438B2 (ja) 2012-10-10
DE602004011553T2 (de) 2009-03-26
RU2006117298A (ru) 2007-12-20
DE602004011553D1 (de) 2008-03-13
JP2007511494A (ja) 2007-05-10
GB0326546D0 (en) 2003-12-17
EP1682113B1 (en) 2008-01-23
ATE384519T1 (de) 2008-02-15
MXPA06005355A (es) 2006-07-10
EP1682113A1 (en) 2006-07-26
WO2005049005A1 (en) 2005-06-02
NO20062118L (no) 2006-05-11
CA2545267A1 (en) 2005-06-02
ES2299884T3 (es) 2008-06-01

Similar Documents

Publication Publication Date Title
EP1682113B1 (en) Inhibitor imaging agents
US20080279765A1 (en) Novel Imaging Agents for Fibrosis
AU2004294784B2 (en) Novel imaging agents comprising caspase-3 inhibitors
US20120244074A1 (en) Labelled integrin binders
JP2009518372A5 (enExample)
US20080279769A1 (en) Enzyme Inhibitor Imaging Agents
US20080292547A1 (en) Novel Imaging Agents for Fibrosis
AU2003273505B2 (en) Improved imaging agents comprising barbituric acid derivatives
US20080279771A1 (en) Novel Imaging Agents for Cancer

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted